-
1دورية أكاديمية
المؤلفون: Fitzpatrick, Orla, Naidoo, Jarushka
المصدر: Lung Cancer: Targets and Therapy ; volume Volume 12, page 123-131 ; ISSN 1179-2728
الإتاحة: https://doi.org/10.2147/lctt.s305466Test
https://www.dovepress.com/getfile.php?fileID=75443Test -
2دورية أكاديمية
المؤلفون: Cappelli, Laura C, Naidoo, Jarushka, Bingham, Clifton O, Shah, Ami A
المساهمون: Jerome L Greene Foundation Scholar Award and the National Institute of Arthritis, Musculoskeletal and Skin Diseases
المصدر: Immunotherapy ; volume 9, issue 1, page 5-8 ; ISSN 1750-743X 1750-7448
-
3دورية أكاديمية
المؤلفون: Brown, Victoria T., Antol, Dana Drzayich, Racsa, Patrick N., Ward, Melea A., Naidoo, Jarushka
المصدر: Cancer Investigation ; volume 39, issue 10, page 789-796 ; ISSN 0735-7907 1532-4192
-
4دورية أكاديمية
المؤلفون: Le, Thomas K., Kaul, Subuhi, Cappelli, Laura C., Naidoo, Jarushka, Semenov, Yevgeniy R., Kwatra, Shawn G.
المصدر: Journal of Dermatological Treatment ; volume 33, issue 3, page 1691-1695 ; ISSN 0954-6634 1471-1753
-
5دورية أكاديمية
المؤلفون: Page, David B, Naidoo, Jarushka, McArthur, Heather L
المصدر: Immunotherapy ; volume 6, issue 2, page 195-209 ; ISSN 1750-743X 1750-7448
الوصف: Although immunogenicity is typically associated with renal cell carcinomas and melanoma, there are several compelling reasons why immune-based therapies should be explored in breast cancer. First, breast cancers express multiple putative tumor-associated antigens, such as HER-2 and MUC-1, which have been the successful focus of vaccine development over the past decade, translating into tumor-specific immune responses and, in some cases, clinical benefit. Second, passive immune strategies with anti-HER-2 antibodies, such as trastuzumab and pertuzumab, have led to survival benefits in breast cancer. Finally, the successes observed with novel immunotherapeutic strategies, such as immune checkpoint blockade and adoptive T-cell therapies in other malignancies, combined with a growing body of literature that supports an interplay between solid tumors and the immune system, indicate that these strategies have the potential to revolutionize the treatment of breast cancer.
